Compare Modine Manufacturing Company (MOD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Modine Manufacturing Company vs Merck & Co., Inc. — how do they compare? Modine Manufacturing Company trades at $184.56 (market cap $10.06B), while Merck & Co., Inc. trades at $142.3 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 35× Modine Manufacturing Company's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Modine Manufacturing Company pays none. Which is the better fit depends on your goals — on Pluang, investors hold Modine Manufacturing Company for 33 Days and Merck & Co., Inc. for 98 Days on average.
| MOD | MRK | |
|---|---|---|
Market Cap | $10.06B | $352.29B |
Volume | 1,340,605 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $283.95 | $156.43 |
52-Week Low | $110.73 | $82.49 |
Typical Hold Time | 33 Days | 98 Days |
Enterprise Value | $10.49B | $399.05B |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Modine Manufacturing (MOD) trades at $189.44, down 0.25% on the day, with a neutral technical signal. The stock shows strong fundamental performance, beating earnings estimates for three consecutive quarters, and benefits from a bullish analyst consensus with a $331.25 price target. Recent corporate actions include the completion of a $946 million spin-off of its Performance Technologies unit, potentially streamlining operations for future growth.
The outlook remains positive given earnings momentum and strategic focus on thermal management solutions, but risks include a high P/E ratio of 70.69 and potential integration challenges post-spin-off. Revenue growth to $3.4B in 2026, though with a declining net margin, suggests scaling operations may pressure profitability near-term.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
